Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 310 entries
Sorted by: Best Match Show Resources per page
Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.

Thoracic cancer

Shi Y, Hu Y, Hu X, Li X, Lin L, Han X.
PMID: 26557919
Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20.

BACKGROUND: This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and the distribution of uridine diphosphate glucuronosyltransferase (UGT1A1). The relationship between UGT1A1 genotypes and patient outcomes was also...

Cite
Shi Y, Hu Y, Hu X, et al. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015;6(6):785-91doi: 10.1111/1759-7714.12303.
Shi, Y., Hu, Y., Hu, X., Li, X., Lin, L., & Han, X. (2015). Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thoracic cancer, 6(6), 785-91. https://doi.org/10.1111/1759-7714.12303
Shi, Yuankai, et al. "Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial." Thoracic cancer vol. 6,6 (2015): 785-91. doi: https://doi.org/10.1111/1759-7714.12303
Shi Y, Hu Y, Hu X, Li X, Lin L, Han X. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20. PMID: 26557919; PMCID: PMC4632933.
Copy Download .nbib Format: NLM
Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice.

Journal of food and drug analysis

Ueng YF, Chen CC, Huang YL, Lee IJ, Yun CH, Chen YH, Huang CC.
PMID: 28911711
J Food Drug Anal. 2015 Sep;23(3):516-528. doi: 10.1016/j.jfda.2015.03.005. Epub 2015 May 21.

Ruta graveolens (the common rue) has been used for various therapeutic purposes, including relief of rheumatism and treatment of circulatory disorder. To elucidate the effects of rue on main drug-metabolizing enzymes, effects of an aqueous extract of the aerial...

Cite
Ueng YF, Chen CC, Huang YL, et al. Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice. J Food Drug Anal. 2015;23(3):516-528doi: 10.1016/j.jfda.2015.03.005.
Ueng, Y. F., Chen, C. C., Huang, Y. L., Lee, I. J., Yun, C. H., Chen, Y. H., & Huang, C. C. (2015). Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice. Journal of food and drug analysis, 23(3), 516-528. https://doi.org/10.1016/j.jfda.2015.03.005
Ueng, Yune-Fang, et al. "Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice." Journal of food and drug analysis vol. 23,3 (2015): 516-528. doi: https://doi.org/10.1016/j.jfda.2015.03.005
Ueng YF, Chen CC, Huang YL, Lee IJ, Yun CH, Chen YH, Huang CC. Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice. J Food Drug Anal. 2015 Sep;23(3):516-528. doi: 10.1016/j.jfda.2015.03.005. Epub 2015 May 21. PMID: 28911711.
Copy Download .nbib Format: NLM
Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.

Case reports in oncological medicine

Jannin A, Hennart B, Adenis A, Chauffert B, Penel N.
PMID: 29098099
Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26.

Alveolar rhabdomyosarcoma (AR) in adult patients is an exceptional malignancy. Management of AR is based on (neo)adjuvant chemotherapy combining ifosfamide, vincristine, and actinomycin D and local curative-intent surgery/radiotherapy. In cases of relapsing AR, the combination of temozolomide/irinotecan is regarded...

Cite
Jannin A, Hennart B, Adenis A, et al. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case Rep Oncol Med. 2017;2017:2683478doi: 10.1155/2017/2683478.
Jannin, A., Hennart, B., Adenis, A., Chauffert, B., & Penel, N. (2017). Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case reports in oncological medicine, 20172683478. https://doi.org/10.1155/2017/2683478
Jannin, Arnaud, et al. "Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism." Case reports in oncological medicine vol. 2017 (2017): 2683478. doi: https://doi.org/10.1155/2017/2683478
Jannin A, Hennart B, Adenis A, Chauffert B, Penel N. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26. PMID: 29098099; PMCID: PMC5634569.
Copy Download .nbib Format: NLM
Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.

SpringerPlus

Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S.
PMID: 24298433
Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013.

Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials investigating the utility of adding fulvestrant to other therapeutics...

Cite
Edavana VK, Penney RB, Yao-Borengasser A, et al. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013;2:620doi: 10.1186/2193-1801-2-620.
Edavana, V. K., Penney, R. B., Yao-Borengasser, A., Williams, S., Rogers, L., Dhakal, I. B., & Kadlubar, S. (2013). Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. SpringerPlus, 2620. https://doi.org/10.1186/2193-1801-2-620
Edavana, Vineetha K, et al. "Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism." SpringerPlus vol. 2 (2013): 620. doi: https://doi.org/10.1186/2193-1801-2-620
Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013. PMID: 24298433; PMCID: PMC3841332.
Copy Download .nbib Format: NLM
Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome.

Pharmacology research & perspectives

Fujiwara R, Itoh T.
PMID: 25505604
Pharmacol Res Perspect. 2014 Oct;2(5):e00053. doi: 10.1002/prp2.53. Epub 2014 Jul 02.

Cytochrome P450 (CYP) 3A4 is a membrane protein that catalyzes hydroxylation of endogenous and exogenous substrates. Protein-protein interaction is a crucial factor that regulates the function of enzymes. However, protein-protein interactions involving human CYPs have not been fully understood....

Cite
Fujiwara R, Itoh T. Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. Pharmacol Res Perspect. 2014;2(5):e00053doi: 10.1002/prp2.53.
Fujiwara, R., & Itoh, T. (2014). Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. Pharmacology research & perspectives, 2(5), e00053. https://doi.org/10.1002/prp2.53
Fujiwara, Ryoichi, and Itoh, Tomoo. "Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome." Pharmacology research & perspectives vol. 2,5 (2014): e00053. doi: https://doi.org/10.1002/prp2.53
Fujiwara R, Itoh T. Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. Pharmacol Res Perspect. 2014 Oct;2(5):e00053. doi: 10.1002/prp2.53. Epub 2014 Jul 02. PMID: 25505604; PMCID: PMC4186418.
Copy Download .nbib Format: NLM
Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.

Evidence-based complementary and alternative medicine : eCAM

Shan L, Yang S, Zhang G, Zhou D, Qiu Z, Tian L, Yuan H, Feng Y, Shi X.
PMID: 24829606
Evid Based Complement Alternat Med. 2014;2014:958937. doi: 10.1155/2014/958937. Epub 2014 Apr 16.

Bavachalcone and corylin are two major bioactive compounds isolated from Psoralea corylifolia L., which has been widely used as traditional Chinese medicine for many years. As two antibiotic or anticancer drugs, bavachalcone and corylin are used in combination with...

Cite
Shan L, Yang S, Zhang G, et al. Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases. Evid Based Complement Alternat Med. 2014;2014:958937doi: 10.1155/2014/958937.
Shan, L., Yang, S., Zhang, G., Zhou, D., Qiu, Z., Tian, L., Yuan, H., Feng, Y., & Shi, X. (2014). Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases. Evidence-based complementary and alternative medicine : eCAM, 2014958937. https://doi.org/10.1155/2014/958937
Shan, Lina, et al. "Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 958937. doi: https://doi.org/10.1155/2014/958937
Shan L, Yang S, Zhang G, Zhou D, Qiu Z, Tian L, Yuan H, Feng Y, Shi X. Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases. Evid Based Complement Alternat Med. 2014;2014:958937. doi: 10.1155/2014/958937. Epub 2014 Apr 16. PMID: 24829606; PMCID: PMC4009204.
Copy Download .nbib Format: NLM
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Pharmaceuticals (Basel, Switzerland)

Saruwatari J, Ishitsu T, Nakagawa K.
PMID: 27713373
Pharmaceuticals (Basel). 2010 Aug 20;3(8):2709-2732. doi: 10.3390/ph3082709.

Genetic polymorphisms in the genes that encode drug-metabolizing enzymes are implicated in the inter-individual variability in the pharmacokinetics and pharmaco-dynamics of antiepileptic drugs (AEDs). However, the clinical impact of these polymorphisms on AED therapy still remains controversial. The defective...

Cite
Saruwatari J, Ishitsu T, Nakagawa K. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel). 2010;3(8):2709-2732doi: 10.3390/ph3082709.
Saruwatari, J., Ishitsu, T., & Nakagawa, K. (2010). Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel, Switzerland), 3(8), 2709-2732. https://doi.org/10.3390/ph3082709
Saruwatari, Junji, et al. "Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy." Pharmaceuticals (Basel, Switzerland) vol. 3,8 (2010): 2709-2732. doi: https://doi.org/10.3390/ph3082709
Saruwatari J, Ishitsu T, Nakagawa K. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel). 2010 Aug 20;3(8):2709-2732. doi: 10.3390/ph3082709. PMID: 27713373; PMCID: PMC4033946.
Copy Download .nbib Format: NLM
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.

International journal of cancer research and molecular mechanisms

Edavana VK, Penney RB, Yao-Borengasser A, Starlard-Davenport A, Dhakal IB, Kadlubar S.
PMID: 26985457
Int J Cancer Res Mol Mech. 2015 Oct;1(3). doi: 10.16966/2381-3318.112. Epub 2015 Sep 22.

Anastrozole is an aromatase inhibitor (AI) used as adjuvant therapy for breast cancer. Anastrozole is subject to direct glucuronidation catalyzed by UDP-glucuronosyltransferase1A4 (UGT1A4). Interindividual variability in anastrozole glucuronidation may be affected by UGT1A4 SNPs. Interplay between drug metabolizing genes...

Cite
Edavana VK, Penney RB, Yao-Borengasser A, et al. Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. Int J Cancer Res Mol Mech. 2015;1(3)doi: 10.16966/2381-3318.112.
Edavana, V. K., Penney, R. B., Yao-Borengasser, A., Starlard-Davenport, A., Dhakal, I. B., & Kadlubar, S. (2015). Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. International journal of cancer research and molecular mechanisms, 1(3), . https://doi.org/10.16966/2381-3318.112
Edavana, Vineetha Koroth, et al. "Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples." International journal of cancer research and molecular mechanisms vol. 1,3 (2015). doi: https://doi.org/10.16966/2381-3318.112
Edavana VK, Penney RB, Yao-Borengasser A, Starlard-Davenport A, Dhakal IB, Kadlubar S. Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. Int J Cancer Res Mol Mech. 2015 Oct;1(3). doi: 10.16966/2381-3318.112. Epub 2015 Sep 22. PMID: 26985457; PMCID: PMC4790825.
Copy Download .nbib Format: NLM
Hydroxylation and sulfation of sex steroid hormones in inflammatory liver.

Journal of biomedical research

Lee SR, Lee SY, Kim SY, Ryu SY, Park BK, Hong EJ.
PMID: 28866654
J Biomed Res. 2017 Sep 26;31(5):437-444. doi: 10.7555/JBR.31.20170031.

Sex steroids, also known as gonadal steroids, are oxidized with hydroxylation by cytochrome P450, glucuronidation by UDP-glucuronosyltransferase, sulfation by sulfotransferase, andO-methylation by catechol O-methyltransferase. Thus, it is important to determine the process by which inflammation influences metabolism of gonadal...

Cite
Lee SR, Lee SY, Kim SY, et al. Hydroxylation and sulfation of sex steroid hormones in inflammatory liver. J Biomed Res. 2017;31(5):437-444doi: 10.7555/JBR.31.20170031.
Lee, S. R., Lee, S. Y., Kim, S. Y., Ryu, S. Y., Park, B. K., & Hong, E. J. (2017). Hydroxylation and sulfation of sex steroid hormones in inflammatory liver. Journal of biomedical research, 31(5), 437-444. https://doi.org/10.7555/JBR.31.20170031
Lee, Sang R, et al. "Hydroxylation and sulfation of sex steroid hormones in inflammatory liver." Journal of biomedical research vol. 31,5 (2017): 437-444. doi: https://doi.org/10.7555/JBR.31.20170031
Lee SR, Lee SY, Kim SY, Ryu SY, Park BK, Hong EJ. Hydroxylation and sulfation of sex steroid hormones in inflammatory liver. J Biomed Res. 2017 Sep 26;31(5):437-444. doi: 10.7555/JBR.31.20170031. PMID: 28866654; PMCID: PMC5706436.
Copy Download .nbib Format: NLM
Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).

Thoracic cancer

Fukuda M, Suetsugu T, Shimada M, Kitazaki T, Hashiguchi K, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Sugio K, Semba H, Nakanishi Y, Ichinose Y.
PMID: 27385990
Thorac Cancer. 2016 Jul;7(4):467-72. doi: 10.1111/1759-7714.12360. Epub 2016 May 11.

BACKGROUND: Uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study.METHODS:...

Cite
Fukuda M, Suetsugu T, Shimada M, et al. Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). Thorac Cancer. 2016;7(4):467-72doi: 10.1111/1759-7714.12360.
Fukuda, M., Suetsugu, T., Shimada, M., Kitazaki, T., Hashiguchi, K., Kishimoto, J., Harada, T., Seto, T., Ebi, N., Takayama, K., Sugio, K., Semba, H., Nakanishi, Y., & Ichinose, Y. (2016). Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). Thoracic cancer, 7(4), 467-72. https://doi.org/10.1111/1759-7714.12360
Fukuda, Minoru, et al. "Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)." Thoracic cancer vol. 7,4 (2016): 467-72. doi: https://doi.org/10.1111/1759-7714.12360
Fukuda M, Suetsugu T, Shimada M, Kitazaki T, Hashiguchi K, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Sugio K, Semba H, Nakanishi Y, Ichinose Y. Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). Thorac Cancer. 2016 Jul;7(4):467-72. doi: 10.1111/1759-7714.12360. Epub 2016 May 11. PMID: 27385990; PMCID: PMC4930967.
Copy Download .nbib Format: NLM
Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease.

Frontiers in aging neuroscience

Ferrer I, Garcia-Esparcia P, Carmona M, Carro E, Aronica E, Kovacs GG, Grison A, Gustincich S.
PMID: 27458372
Front Aging Neurosci. 2016 Jul 05;8:163. doi: 10.3389/fnagi.2016.00163. eCollection 2016.

Olfactory receptors (ORs) and down-stream functional signaling molecules adenylyl cyclase 3 (AC3), olfactory G protein α subunit (Gαolf), OR transporters receptor transporter proteins 1 and 2 (RTP1 and RTP2), receptor expression enhancing protein 1 (REEP1), and UDP-glucuronosyltransferases (UGTs) are...

Cite
Ferrer I, Garcia-Esparcia P, Carmona M, et al. Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Front Aging Neurosci. 2016;8:163doi: 10.3389/fnagi.2016.00163.
Ferrer, I., Garcia-Esparcia, P., Carmona, M., Carro, E., Aronica, E., Kovacs, G. G., Grison, A., & Gustincich, S. (2016). Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Frontiers in aging neuroscience, 8163. https://doi.org/10.3389/fnagi.2016.00163
Ferrer, Isidro, et al. "Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease." Frontiers in aging neuroscience vol. 8 (2016): 163. doi: https://doi.org/10.3389/fnagi.2016.00163
Ferrer I, Garcia-Esparcia P, Carmona M, Carro E, Aronica E, Kovacs GG, Grison A, Gustincich S. Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Front Aging Neurosci. 2016 Jul 05;8:163. doi: 10.3389/fnagi.2016.00163. eCollection 2016. PMID: 27458372; PMCID: PMC4932117.
Copy Download .nbib Format: NLM
FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping.

OncoTargets and therapy

Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY.
PMID: 25473295
Onco Targets Ther. 2014 Nov 21;7:2143-6. doi: 10.2147/OTT.S69774. eCollection 2014.

Here we report a case of metastatic colon cancer treated with 5-fluorouracil, leucovorin, and escalated doses of irinotecan (FOLFIRI) combined with regorafenib in the fourth-line setting after uridine diphosphate glucuronosyltransferase (UGT)1A1 genotyping analysis. A 66-year-old male was initially diagnosed...

Cite
Lu CY, Yeh YS, Huang CW, et al. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther. 2014;7:2143-6doi: 10.2147/OTT.S69774.
Lu, C. Y., Yeh, Y. S., Huang, C. W., Ma, C. J., Yu, F. J., & Wang, J. Y. (2014). FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. OncoTargets and therapy, 72143-6. https://doi.org/10.2147/OTT.S69774
Lu, Chien-Yu, et al. "FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping." OncoTargets and therapy vol. 7 (2014): 2143-6. doi: https://doi.org/10.2147/OTT.S69774
Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther. 2014 Nov 21;7:2143-6. doi: 10.2147/OTT.S69774. eCollection 2014. PMID: 25473295; PMCID: PMC4246994.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 310 entries